Greenlife Pharmaceutical Limited, a leading pharmaceutical company in Nigeria, has officially unveiled its latest innovation, P-Alaxin DS 80/640, at the 2025 ACPN Continuous Education Conference held at Yard 158, Oregun, Lagos. The event attracted key stakeholders in the pharmaceutical industry, who hailed the launch as a major milestone in malaria treatment.
Speaking at the unveiling, Pharm. Derick Osondu, general manager, Sales and Marketing, Greenlife Pharmaceutical Limited, highlighted that P-Alaxin DS is part of Greenlife Pharmaceutical Limited’s broader mission to combat malaria in Nigeria and across Africa, ensuring access to high-quality, reliable antimalarial medications.
He added that Greenlife’s P-Alaxin TS complements this innovation by offering another effective treatment option. With formulations aligned with international best practices, both P-Alaxin DS and P-Alaxin TS serve as reliable solutions for malaria treatment and prevention.
“By addressing these challenges, Greenlife Pharmaceutical Limited reinforces its dedication to the fight against malaria and the overall improvement of healthcare in Nigeria. With this latest innovation, the Pharma company continues to strengthen its position as a leader in the pharmaceutical industry, committed to delivering quality and impactful medical solutions,” he said.
Speaking in the same vein, Pharm. Henry Okolo, Brand Development Manager at Greenlife Pharmaceutical Limited, said P-Alaxin DS 80/640 is a cutting-edge antimalarial medication formulated to combat malaria effectively as it contains dihydroartemisinin and piperaquine phosphate, a combination recommended by the World Health Organization (WHO) for its high efficacy and ability to prevent recurrence.
He emphasised the significance of P-Alaxin DS in improving patient adherence and treatment outcomes, adding that medication adherence remains a significant challenge in malaria treatment, and P-Alaxin DS is designed to address this issue through its innovative formulation.
“The drug enhances patient compliance while maintaining the highest efficacy standards, reaffirming Greenlife’s commitment to providing top-quality pharmaceutical solutions that positively impact lives,” he said.
Okolo also underscored Greenlife Pharmaceutical Limited’s relentless fight against drug counterfeiting and its dedication to a malaria-free environment for over two decades. He noted that Greenlife has been marketing P-Alaxin Tablets in Nigeria for over 16 years and remains steadfast in upholding the quality of its products.
At the unveiling, Pharm. Gafar Madehin, national secretary of the Pharmaceutical Society of Nigeria (PSN), described P-Alaxin DS as a groundbreaking innovation poised to revolutionize malaria treatment in Nigeria.
He praised the drug’s ability to reduce pill burden, which enhances compliance and ultimately improves treatment outcomes. He affirmed that the medication would significantly contribute to the fight against malaria in the country.
Similarly, Pharm. Tolu Ajayi, chairman of the Association of Community Pharmacists of Nigeria (ACPN), Lagos Chapter, lauded Greenlife for its unwavering commitment to innovation and quality. He commended the company for being an outstanding partner of the conference and expressed pride in ACPN’s association with Greenlife.
Ajayi further emphasised the importance of adherence in medication use, noting that patient convenience is crucial and efficacy is non-negotiable. He praised Greenlife for consistently maintaining high-quality standards, highlighting its long-standing reputation in the pharmaceutical industry as a formidable force.
“The unveiling of P-Alaxin DS marks a significant advancement in malaria management. The two tablets once-daily dosing regimen is designed to address concerns of pill burden and non-compliance, ensuring better adherence and treatment success,” Ajayi stated.
